Preparation and initial characterization of biodegradable particles containing gadolinium-DTPA contrast agent for enhanced MRI

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 45, 2008, Pages 17232-17237

  Doiron, Amber L ^a   Chu, Kevin ^a   Ali, Adeel ^b   Brannon Peppas, Lisa ^c  

^a The University of Texas at Austin   (United States)

^b Law Offices of R V Reddy   (United States)

^c Appian Labs LLC   (United States)

Author keywords

Atherosclerosis; Imaging; PEG; PLGA; Targeted

Indexed keywords

GADOLINIUM PENTETATE; POLYGLACTIN; POLYLACTIDE POLY(ETHYLENE GLYCOL); POLYMER; UNCLASSIFIED DRUG; WATER OIL CREAM;

ARTICLE; ATHEROSCLEROSIS; BIODEGRADATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYTOTOXICITY; ENCAPSULATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYDROPHILICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPE; TRANSMISSION ELECTRON MICROSCOPY; UMBILICAL VEIN; ZETA POTENTIAL;

ATHEROSCLEROSIS; CELL LINE; CONTRAST MEDIA; ENDOTHELIAL CELLS; GADOLINIUM DTPA; HUMANS; LACTIC ACID; MAGNETIC RESONANCE IMAGING; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; POLYGLYCOLIC ACID;

EID: 56249127544     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0710205105     Document Type: Article

References (33)

1. Rosamond W, et al., for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2007) Heart disease and stroke statistics - 2007 update - A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115:e69-e171.
2. Brown BG, et al. (1986) Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: Quantitative angiographic observations. Circulation 73:653-661.
3. Ambrose JA, et al. (1988) Angiographic progression of coronary-artery disease and the development of myocardial-infarction. J Am Coll Cardiol 12:56-62.
4. Little WC, et al. (1988) Can coronary angiography predict the site of a subsequent myocardial-infarction in patients with mild-to-moderate coronary-artery disease. Circulation 78:1157-1166.
5. Glagov S, Weisenberg E, Zarins CK (1987) Compensatory enlargement of human atherosclerotic coronary-arteries. N Engl J Med 316:1371-1375.
6. Rudd JHF, Davies JR, Weissberg PL (2005) Imaging of atherosclerosis - Can we predict plaque rupture? Trends Cardiovasc Med 15:17-24.
7. Stary HC, et al. (1994) A definition of initial, fatty streak, and intermediate lesions of atherosclerosis - A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 89:2462-2478.
8. Stary HC, et al. (1995) A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis - A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 92:1355-1374.
9. Dalager-Pedersen S, Pedersen EM, Ringgaard S, Falk E (1999) in The Vulnerable Atherosclerotic Plaque: Understanding, Identification, and Modification, ed Fuster V (Blackwell, New York), pp 1-23.
10. Choudhury RP, Fuster V, Fayad ZA (2004) Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discovery 3:913-925.
11. Cai JM, et al. (2002) Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. Circulation 106:1368-1373.
12. Luk-Pat GT, Gold GE, Olcott EW, Hu BS, Nishimura DG (1999) High-resolution three-dimensional in vivo imaging of atherosclerotic plaque. Magn Reson Med 42:762-771.
13. Fayad ZA, Fuster V (2001) Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ Res 89:305-316.
14. Jain RA (2000) The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21:2475-2490.
15. Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Delivery Rev 56:1649-1659.
16. Funovics MA, et al. (2004) MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging 22:843-850.
17. Gohr-Rosenthal S, Schmitt-Willich H, Ebert W, Conrad J (1993) The demonstration of human tumors on nude mice using gadolinium-labeled monoclonal-antibodies for magnetic resonance imaging. Invest Radiol 28:789-795.
18. Faranesh AZ, et al. (2004) In vitro release of vascular endothelial growth factor from gadolinium-doped biodegradable microspheres. Magn Reson Med 51:1265-1271.
19. Lipinski MJ, et al. (2006) MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med 56:601-610.
20. Ayyagari AL, et al. (2006) Long-circulating liposomal contrast agents for magnetic resonance imaging. Magn Reson Med 55:1023-1029.
21. Robertson JD, Crane SB, Wickline SA, Lanza GM (2005) Characterization and biodistribution of a novel MRI molecular imaging agent by neutron activation analysis. J Radioanal Nucl Chem 263:511-514.
22. Winter PM, et al. (2003) Molecular imaging of angiogenesis in early-stage atherosclerosis with α(v)β(3)-integrin-targeted nanoparticles. Circulation 108:2270-2274.
23. Flacke S, et al. (2001) Novel MRI contrast agent for molecular imaging of fibrin: Implications for detecting vulnerable plaques. Circulation 104:1280-1285.
24. Reynolds CH, et al. (2000) Gadolinium-loaded nanoparticles: New contrast agents for magnetic resonance imaging. J Am Chem Soc 122:8940-8945.
25. Chen HH, et al. (2005) MR imaging of biodegradable polymeric microparticles: A potential method of monitoring local drug delivery. Magn Reson Med 53:614-620.
26. Amirbekian V, et al. (2007) Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci USA 104:961-966.
27. Tokumitsu H, Ichikawa H, Fukumori Y (1999) Chitosan-gadopentetic acid complex nanoparticles for gadolinium neutron-capture therapy of cancer: Preparation by novel emulsion-droplet coalescence technique and characterization. Pharm Res 16:1830-1835.
28. Decuzzi P, Lee S, Bhushan B, Ferrari M (2005) A theoretical model for the margination of particles within blood vessels. Ann Biomed Eng 33:179-190.
29. Owens DE, Peppas NA (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307:93-102.
30. Chaw CS, Yang YY, Lim IJ, Phan TT (2003) Water-soluble β-methasone-loaded poly-(lactide-co-glycolide) hollow microparticles as a sustained release dosage form. J Microencapsulation 20:349-359.
31. Quellec P, et al. (1998) Protein encapsulation within polyethylene glycol-coated nanospheres I. Physicochemical characterization. J Biomed Mater Res 42:45-54.
32. De Jaeghere F, et al. (1999) Formulation and lyoprotection of poly(lactic acid-coethylene oxide) nanoparticles: Influence on physical stability and in vitro cell uptake. Pharm Res 16:859-866.
33. Chacon M, Molpeceres J, Berges L, Guzman M, Aberturas MR (1999) Stability and freeze-drying of cyclosporine loaded poly(D,L-lactide-glycolide) carriers. Eur J Pharm Sci 8:99-107.